Background: Sulfur mustard was the most widely applied chemical warfare agent by the Iraqi army in Iran–Iraq war (1983-1988). Considering the role of sulfur mustard toxicity in hematopoietic neoplasms and also new role of JAK2 mutation in these neoplasms, we assessed this mutation and delayed hematologic complications in veterans exposed to sulfur mustard. Methods: This case control study was performed in Mashhad University of Medical Sciences, Mashhad, Iran in collaboration with Janbasan Foundation of Khorasan Razavi, Iran in 2012. The case group consists of 42 patients who exposed to sulfur mustard about 30 yr ago and the control group includes 30 healthy persons. For all subjects complete blood counts and ARMSpolymerase chain reaction for JAK2 (V617F) mutation was carried out. Data were analyzed by statistical software using independent sample t-testand Mann- Whitney U test. Results: JAK2 (V617F) mutation was detected, neither in the sulfur mustardveterans nor in the control group. Moreover no significant difference was detected in hematologic parameters between the two groups. Conclusion: Despite sulfur mustard can increase risk of tumor genesis especially hematologic neoplasms but this is probablyas result of other genetic mechanism apart from JAK2 mutation. Considering the health and importance of preventive measure for the sulfur mustard victims, we suggest other genetic aspects of tumor genesis to be assessed in these patients.
Introduction: Apoptosis is an important mechanism in both physiological and pathological conditions. The BCL2 family of proteins plays a critical role in regulation of apoptotic cell death. Up and down regulation of BCL2-like 12 (BCL2L12), a new member of the BCL2 family, has been reported in several malignancies. However, the expression level of BCL2L12 rarely has been studied in leukemia. This study was designed to investigate the mRNA expression of BCL2L12 in patients with acute leukemia. Materials and methods: 90 patients with acute leukemia as case group and 90 healthy persons as controls, were participated this study. RNA was extracted from peripheral blood samples. Expression level of BCL2L12 mRNA was evaluated by a quantitative real-time polymerase chain reaction (qRT-PCR) method and its association with clinical and laboratory findings was analyzed. Results: The expression of BCL2L12 mRNA was significantly lower in acute lymphoblastic leukemia (ALL) cases comparing the controls (P<0.001), while it was not significantly different in acute myeloid leukemia (AML) samples compared the control group. In addition, there were higher BCL2L12 level in females (than in males) and in patients with t(12;21) in ALL patients. There was no association between BCL2L12 expression level and other clinical and laboratory findings of AML patients. Conclusion: BCL2L12 seems play a role in the pathogenesis of ALL. Further studies with larger sample size is needed to clarify its probable impact on prognosis and therapeutic response.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.